| Literature DB >> 32773390 |
Ji-Hye Lee1, Si-Hyong Jang1, Nam-Jun Cho2, Nam Hun Heo3, Hyo-Wook Gil2, Eun Young Lee2,4, Jong-Seok Moon5, Samel Park2,5.
Abstract
BACKGROUND: Proteinuria is a significant risk factor for progression of IgA nephropathy (IgAN) and has a positive correlation with severity of foot process effacement (FPE). We evaluated the relationship of FPE with proteinuria and histologic characteristics, including the Oxford classification.Entities:
Keywords: Glomerulonephritis; Immunoglobulin A; Nephropathy; Podocytes; Proteinuria
Year: 2020 PMID: 32773390 PMCID: PMC7530366 DOI: 10.23876/j.krcp.20.017
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
Figure 1Representative histology by light microscopy of glomeruli with (A) mesangial hypercellularity and (B) endocapillary hypercellularity.
Black bar represents 50 μm; black arrowheads, mesangial hypercellularity; black arrows, endocapillary hypercellularity.
Figure 2Representative images of electron microscopy of (A) rare, (B) mild, (C) moderate, and (D) diffuse foot process effacement.
White bar represents 5 μm in (A), (B), and (C) but 10 μm in (D). Black arrows represent lesion with foot process effacement.
Clinical characteristics of patients with IgA nephropathy stratified according to foot process effacement (n = 245)
| Characteristic | Rare FPE (n = 46) | Mild FPE (n = 111) | Moderate FPE (n = 67) | Diffuse FPE (n = 21) | |
|---|---|---|---|---|---|
| Age (yr) | 33 (23-49) | 38 (30-48) | 40 (31-46) | 39 (31-49) | 0.655 |
| Male | 30 (65.2) | 64 (57.7) | 36 (53.7) | 13 (61.9) | 0.656 |
| HTN | 14 (30.4) | 33 (29.7) | 22 (32.8) | 8 (38.1) | 0.664 |
| Current smoker | 9 (19.6) | 20 (18.0) | 9 (13.4) | 3 (14.3) | 0.799 |
| BMI (kg/m2) | 24.0 (21.2-26.7) | 23.8 (21.0-26.4) | 23.2 (21.5-26.4) | 23.1 (21.4-26.5) | 0.870 |
| MAP (mmHg) | 89 (76-97) | 93 (83-97) | 93 (83-97) | 93 (82-107) | 0.403 |
| WBC count (/μL) | 7,105 (5,933-8,165) | 6,710 (5,820-8,120) | 7,080 (5,590-8,720) | 6,640 (5,630-8,405) | 0.823 |
| Hemoglobin (g/dL) | 13.8 ± 1.6 | 13.7 ± 1.6 | 13.5 ± 1.8 | 12.8 ± 2.6 | 0.118 |
| Platelet count (/μL) | 264 (233-289) | 251 (213-291) | 245 (217-284) | 224 (200-262) | 0.122 |
| Protein (g/dL) | 6.9 (6.5-7.2) | 6.8 (6.3-7.2) | 6.7 (6.2-7.2) | 6.1 (4.8-6.9) | 0.002 |
| Albumin (g/dL) | 4.2 (4.0-4.4) | 4.2 (3.9-4.4) | 4.1 (3.8-4.3) | 3.7 (2.5-4.3) | 0.005 |
| BUN (mg/dL) | 13.8 (11.1-16.1) | 14.5 (12.6-17.8) | 15.7 (12.2-19.3) | 16.7 (12.3-27.5) | 0.064 |
| Creatinine (mg/dL) | 0.84 (0.70-0.99) | 0.87 (0.70-1.10) | 1.00 (0.80-1.20) | 1.20 (0.85-1.70) | < 0.001 |
| eGFR (mL/min per 1.73 m2) | 103.5 (93.2-123.4) | 108.0 (77.8-122.3) | 88.4 (64.5-112.6) | 71.1 (37.2-107.9) | < 0.001 |
| Uric acid (mg/dL) | 5.8 (4.4-6.5) | 5.7 (4.8-6.6) | 6.2 (4.6-7.4) | 7.0 (5.7-9.1) | 0.008 |
| Calcium (mg/dL) | 9.3 (9.2-9.6) | 9.2 (8.8-9.4) | 9.1 (8.7-9.5) | 8.6 (7.9-9.1) | < 0.001 |
| Corrected calcium (mg/dL) | 9.1 ± 0.3 | 9.0 ± 0.4 | 9.0 ± 0.5 | 8.9 ± 0.5 | 0.256 |
| Phosphorus (mg/dL) | 3.5 ± 0.5 | 3.6 ± 0.6 | 3.5 ± 0.5 | 3.8 ± 0.8 | 0.218 |
| Urine protein (g/day) | 0.38 (0.16-0.70) | 0.60 (0.35-1.25) | 0.60 (0.33-1.45) | 0.74 (0.38-2.70) | 0.003 |
| PCR (g/g) | 0.30 (0.15-0.52) | 0.55 (0.28-1.13) | 0.58 (0.34-1.12) | 1.22 (0.29-2.21) | < 0.001 |
| Total glomeruli (counts) | 32 (18-42) | 23 (16-35) | 22 (13-34) | 22 (14-26) | 0.038 |
| Glomerulosclerosis (%) | 5.9 (0.0-16.3) | 8.7 (1.3-23.1) | 18.8 (6.7-42.1) | 16.2 (5.2-33.7) | < 0.001 |
| GSG abnormal for age | 17 (37.0) | 51 (45.9) | 45 (67.2) | 11 (52.4) | 0.008 |
| Oxford classification | |||||
| M1 | 14 (30.4) | 49 (44.1) | 44 (65.7) | 11 (52.4) | 0.002 |
| E1 | 23 (50.0) | 52 (46.8) | 35 (52.2) | 11 (52.4) | 0.899 |
| S1 | 34 (73.9) | 94 (84.7) | 57 (85.1) | 16 (76.2) | 0.321 |
| T1 | 4 (8.7) | 25 (22.5) | 19 (28.4) | 6 (28.6) | 0.009b,c |
| T2 | 0 (0.0) | 2 (1.8) | 6 (9.0) | 0 (0.0) | |
| C1 | 13 (28.3) | 37 (33.3) | 23 (34.3) | 3 (14.3) | 0.280 |
| C2 | 1 (2.2) | 1 (0.9) | 0 (0.0) | 1 (4.8) |
Data are presented as mean ± standard deviation, median (interquartile range), or number (%) as appropriate.
BMI, body mass index; BUN, blood urea nitrogen; C, crescents; E, endocapillary hypercellularity; eGFR, estimated glomerular filtration rate; FPE, foot process effacement; GSG, globally sclerotic glomeruli; HTN, hypertension; M, mesangial hypercellularity; MAP, mean arterial pressure; PCR, urine protein to creatinine ratio; S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis; WBC, white blood cell.
aP value was calculated using one-way ANOVA. In other cases, it was calculated using the Kruskal–Wallis test. bStatistical significance in the trend test. For continuous variables, the Jonckheere–Terpstra test was used. For categorical variables, Cochran–Armitage (only for 2 × k tables) or linear-by-linear test was used. cFisher’s exact test was used.
Figure 3Characteristics of renal histology according to stratification of severity of foot process effacement.
Represented based on (A-C) immunofluorescence stain, (A) IgA, (B) IgG, (C), C3, and (D) globally sclerotic glomeruli (GSG) abnormal or normal for age. The numbers in the graph indicate the numbers of patients. Statistical significance in trend test; aP < 0.01; bP < 0.05.
Figure 4Degree of proteinuria based on the Oxford classification.
(A) Mesangial hypercellularity, M; (B) endocapillary hypercellularity, E; (C) segmental glomerulosclerosis, S; (D) tubular atrophy/interstitial fibrosis, T; and (E) crescents, C. Presented as median and interquartile range; *P < 0.05; ***P < 0.001.
The clinical and histologic characteristics associated with level of urine protein (g/day)
| Variable | Model 1 | Model 2 | |||
|---|---|---|---|---|---|
| β (95% CI) | β (95% CI) | ||||
| Age, per 10 years | -0.04 (-0.19 to 0.12) | 0.655 | -0.03 (-0.18 to 0.12) | 0.713 | |
| Male | 0.20 (-0.19 to 0.60) | 0.312 | 0.26 (-0.12 to 0.64) | 0.185 | |
| HTN | -0.08 (-0.49 to 0.32) | 0.689 | 0.01 (-0.39 to 0.40) | 0.977 | |
| Current smoker | 0.10 (-0.34 to 0.54) | 0.651 | 0.13 (-0.29 to 0.56) | 0.544 | |
| BMI, per 1 kg/m2 | 0.04 (-0.00 to 0.09) | 0.058 | 0.05 (0.01 to 0.09) | 0.023 | |
| MAP, per 1 mmHg | 0.02 (0.00 to 0.03) | 0.011 | 0.01 (0.00 to 0.03) | 0.032 | |
| eGFR, per 10 mL/min/1.73 m2 | -0.12 (-0.21 to -0.03) | 0.009 | -0.09 (-0.18 to 0.00) | 0.052 | |
| Uric acid, per mg/dL | -0.04 (-0.16 to 0.09) | 0.545 | -0.07 (-0.19 to 0.05) | 0.271 | |
| Oxford classification | |||||
| M1 (vs. M0) | 0.09 (-0.25 to 0.43) | 0.621 | 0.04 (-0.29 to 0.38) | 0.799 | |
| E1 (vs. E0) | 0.51 (0.16 to 0.87) | 0.004 | 0.53 (0.19 to 0.87) | 0.002 | |
| S1 (vs. S0) | -0.38 (-0.82 to 0.05) | 0.084 | -0.40 (-0.82 to 0.03) | 0.067 | |
| T1/2 (vs. T0) | -0.02 (-0.48 to 0.44) | 0.942 | 0.03 (-0.43 to 0.48) | 0.912 | |
| C1/2 (vs. C0) | 0.08 (-0.31 to 0.46) | 0.690 | 0.14 (-0.23 to 0.52) | 0.457 | |
| Foot process effacement | |||||
| Rare | Reference | ||||
| Mild | 0.47 (0.05 to 0.89) | 0.028 | |||
| Moderate | 0.50 (0.02 to 0.97) | 0.042 | |||
| Diffuse | 1.30 (0.63 to 1.96) | < 0.001 | |||
Multivariable generalized linear model was used (n = 245).
BMI, body mass index; C, crescents; CI, confidence interval; E, endocapillary hypercellularity; eGFR, estimated glomerular filtration rate; HTN, hypertension; M, mesangial hypercellularity; MAP, mean arterial pressure; S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis.
The histologic characteristics associated with severity of foot process effacement
| Variable | Odds ratios (95% CI) | |
|---|---|---|
| Oxford classification | ||
| M1 (vs. M0) | 1.90 (1.10-3.26) | 0.021 |
| E1 (vs. E0) | 1.16 (0.68-2.00) | 0.586 |
| S1 (vs. S0) | 1.10 (0.55-2.20) | 0.781 |
| T1/2 (vs. T0) | 1.79 (0.96-3.34) | 0.065 |
| C1/2 (vs. C0) | 0.68 (0.38-1.23) | 0.206 |
| Immunofluorescence | ||
| IgA | ||
| 1+ | Reference | |
| 2+ | 0.90 (0.49-1.65) | 0.737 |
| ≥ 3+ | 0.52 (0.20-1.32) | 0.170 |
| IgG | ||
| Negative | Reference | |
| Positive | 3.77 (1.66-8.54) | 0.001 |
| C3 | ||
| Negative | Reference | |
| Trace | 2.09 (0.26-16.94) | 0.489 |
| 1+ | 0.88 (0.13-6.21) | 0.901 |
| ≥ 2+ | 1.12 (0.14-8.79) | 0.912 |
| Age-adjusted glomerulosclerosis | ||
| GSG normal for age | Reference | |
| GSG abnormal for age | 1.57 (0.89-2.79) | 0.122 |
Multivariable ordinary logistic analysis was used (n = 245).
C, crescents; CI, confidence interval; E, endocapillary hypercellularity; GSG, globally sclerotic glomeruli; M, mesangial hypercellularity; S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis.
Figure 5The association of endocapillary hypercellularity and crescents and their implications on proteinuria.
(A) Crescents are more prevalent in endocapillary hypercellularity, P < 0.001 by Pearson’s chi-square test. (B) The amount of proteinuria is larger in endocapillary hypercellularity, irrespective of crescents. **P < 0.01; ***P < 0.001 by Kruskal–Wallis and Dunn’s multiple comparisons test.
C, crescents; E, endocapillary hypercellularity.